Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fredrik Lehmann

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Molecular Diversity|February 12, 2004
Efficient large scale microwave assisted Mannich reactions using substituted acetophenonesFredrik Lehmann, Ake Pilotti, Kristina Luthman
Molecules (Basel, Switzerland)|October 13, 2021
Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer TherapyJakob Lindberg, Johan Nilvebrant, Per-Åke Nygren, et al.
Organic Letters|October 10, 2009
A versatile new synthetic route to 1N-hydroxyindazolesFredrik Lehmann, Tobias Koolmeister, Luke R Odell, et al.
Bioorganic & Medicinal Chemistry|March 23, 2005
Isochromanone-based urotensin-II receptor agonistsFredrik Lehmann, Erika A Currier, Roger Olsson, et al.
The Analyst|October 6, 2018
Qualitative analysis of antibody-drug conjugates (ADCs): an experimental comparison of analytical techniques of cysteine-linked ADCsMalin Källsten, Rafael Hartmann, Konstantin Artemenko, et al.
European Journal of Medicinal Chemistry|November 23, 2006
Design, parallel synthesis and SAR of novel urotensin II receptor agonistsFredrik Lehmann, Lisa Lake, Erika A Currier, et al.
Antibodies (Basel, Switzerland)|September 11, 2020
Investigating the Impact of Sample Preparation on Mass Spectrometry-Based Drug-To-Antibody Ratio Determination for Cysteine- and Lysine-Linked Antibody-Drug ConjugatesMalin Källsten, Rafael Hartmann, Lucia Kovac, et al.
Leukemia Research|January 10, 2021
Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugsKonstantin Byrgazov, Marianne Kraus, Andrej Besse, et al.
Hemasphere|June 17, 2021
Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor CellsKonstantin Byrgazov, Andrej Besse, Marianne Kraus, et al.
Journal of Medicinal Chemistry|March 31, 2006
Novel potent and efficacious nonpeptidic urotensin II receptor agonistsFredrik Lehmann, Anna Pettersen, Erika A Currier, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Molecular Diversity|February 12, 2004
Efficient large scale microwave assisted Mannich reactions using substituted acetophenonesFredrik Lehmann, Ake Pilotti, Kristina Luthman
Molecules (Basel, Switzerland)|October 13, 2021
Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer TherapyJakob Lindberg, Johan Nilvebrant, Per-Åke Nygren, et al.
Organic Letters|October 10, 2009
A versatile new synthetic route to 1N-hydroxyindazolesFredrik Lehmann, Tobias Koolmeister, Luke R Odell, et al.
Bioorganic & Medicinal Chemistry|March 23, 2005
Isochromanone-based urotensin-II receptor agonistsFredrik Lehmann, Erika A Currier, Roger Olsson, et al.
The Analyst|October 6, 2018
Qualitative analysis of antibody-drug conjugates (ADCs): an experimental comparison of analytical techniques of cysteine-linked ADCsMalin Källsten, Rafael Hartmann, Konstantin Artemenko, et al.
European Journal of Medicinal Chemistry|November 23, 2006
Design, parallel synthesis and SAR of novel urotensin II receptor agonistsFredrik Lehmann, Lisa Lake, Erika A Currier, et al.
Antibodies (Basel, Switzerland)|September 11, 2020
Investigating the Impact of Sample Preparation on Mass Spectrometry-Based Drug-To-Antibody Ratio Determination for Cysteine- and Lysine-Linked Antibody-Drug ConjugatesMalin Källsten, Rafael Hartmann, Lucia Kovac, et al.
Leukemia Research|January 10, 2021
Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugsKonstantin Byrgazov, Marianne Kraus, Andrej Besse, et al.
Hemasphere|June 17, 2021
Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor CellsKonstantin Byrgazov, Andrej Besse, Marianne Kraus, et al.
Journal of Medicinal Chemistry|March 31, 2006
Novel potent and efficacious nonpeptidic urotensin II receptor agonistsFredrik Lehmann, Anna Pettersen, Erika A Currier, et al.
Pageof 4